Jul 28 |
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
|
Jul 27 |
AbbVie Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
Jul 26 |
AbbVie's Immunology Products Continue to Deliver, Morgan Stanley Says
|
Jul 26 |
AbbVie exits Alzheimer’s program on lack of differentiation
|
Jul 26 |
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
|
Jul 26 |
Two biotechs cut staff; AbbVie weathers biosimilar threat
|
Jul 26 |
AbbVie’s Q2 2024 net earnings drop to $1.37bn
|
Jul 26 |
Company News for Jul 26, 2024
|
Jul 26 |
Q2 2024 AbbVie Inc Earnings Call
|
Jul 26 |
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
|